With the thumbs up for Amgen Inc.'s Evenity (romosozumab-aqqg) and Janssen Pharmaceutical Cos.'s Balversa (erdafitinib), the US FDA's Center for Drug Evaluation and Research issued its seventh and eighth novel product approvals of 2019.
ViiV Healthcare made noise on the non-novel drug front with an FDA nod for Dovato (dolutegravir and lamivudine),...








